Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing cancer immunotherapy trials: back to basics.

Freda K Stevenson1, Jason Rice

  • 1Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, UK. fs@soton.ac.uk

European Journal of Immunology
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The singularity of IGHV4-34 links infection, autoimmunity, and B-cell tumors.

Blood·2026
Same author

Friends in need: The value of supportive colleagues in research.

HemaSphere·2025
Same author

Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.

Blood·2024
Same author

The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells.

Blood·2023
Same author

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.

Leukemia·2023
Same author

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.

Blood advances·2022
Same journal

Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

European journal of immunology·2026
Same journal

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same journal

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European journal of immunology·2026
Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026
Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026
See all related articles

Developing effective cancer vaccines requires breaking immune tolerance to self-antigens and optimizing antigen delivery. Immunological principles from mouse studies guide clinical cancer vaccine design, focusing on T-cell activation and antigen presentation strategies.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer vaccine development benefits from understanding immune regulation.
  • Translating murine study findings to human clinical applications is crucial.
  • Overcoming self-antigen tolerance is a key challenge in cancer immunotherapy.

Purpose of the Study:

  • To define molecular approaches for cancer vaccine development prior to clinical testing.
  • To explore strategies for breaking immune tolerance against cancer targets.
  • To optimize antigen delivery and T-cell help for enhanced cancer vaccine efficacy.

Main Methods:

  • Utilizing xenogeneic antigens to break tolerance (with variable outcomes).
  • Investigating prime/boost vaccination strategies (DNA priming, viral vector boosting).

Related Experiment Videos

  • Exploring physical methods like electroporation for enhanced antigen delivery.

    • Main Results:

    • Xenogeneic antigen use showed variable success in breaking tolerance.
    • Prime/boost strategies can induce blocking immunity, requiring careful application.
    • Electroporation offers a physical method to enhance immune responses.

    Conclusions:

    • Applying immunological logic to cancer vaccines can address T-cell help and antigen delivery challenges.
    • Harnessing antimicrobial repertoires may effectively activate T-cell help.
    • Careful consideration of vaccination strategies is vital for successful clinical translation.